Actavis' planned acquisition of Allergan has been completed, following approval by the shareholders of both companies. The transaction, which is worth about $70.5 billion, creates one of the ten largest pharmaceutical companies in the world, with combined revenues expected to reach more than $23 billion in 2015. As previously reported, Actavis will change its name to Allergan after the takeover.

Topics